- Home
- TARA vs BIVI Comparison
TARA vs BIVI Comparison
Compare TARA & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARA
- BIVI
- Stock Information
- Founded
- TARA N/A
- BIVI 2013
- Country
- TARA United States
- BIVI United States
- Employees
- TARA N/A
- BIVI N/A
- Industry
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- TARA Health Care
- BIVI Health Care
- Exchange
- TARA Nasdaq
- BIVI Nasdaq
- Market Cap
- TARA 52.4M
- BIVI 49.8M
- IPO Year
- TARA N/A
- BIVI N/A
- Fundamental
- Price
- TARA $5.30
- BIVI $2.39
- Analyst Decision
- TARA Strong Buy
- BIVI Strong Buy
- Analyst Count
- TARA 3
- BIVI 1
- Target Price
- TARA $22.67
- BIVI $30.00
- AVG Volume (30 Days)
- TARA 6.6M
- BIVI 1.7M
- Earning Date
- TARA 11-12-2024
- BIVI 02-11-2025
- Dividend Yield
- TARA N/A
- BIVI N/A
- EPS Growth
- TARA N/A
- BIVI N/A
- EPS
- TARA N/A
- BIVI N/A
- Revenue
- TARA N/A
- BIVI N/A
- Revenue This Year
- TARA N/A
- BIVI N/A
- Revenue Next Year
- TARA N/A
- BIVI N/A
- P/E Ratio
- TARA N/A
- BIVI N/A
- Revenue Growth
- TARA N/A
- BIVI N/A
- 52 Week Low
- TARA $1.60
- BIVI $1.04
- 52 Week High
- TARA $10.48
- BIVI $33.10
- Technical
- Relative Strength Index (RSI)
- TARA 63.59
- BIVI 39.73
- Support Level
- TARA $5.27
- BIVI $2.21
- Resistance Level
- TARA $6.39
- BIVI $2.70
- Average True Range (ATR)
- TARA 0.89
- BIVI 0.22
- MACD
- TARA 0.05
- BIVI -0.08
- Stochastic Oscillator
- TARA 36.25
- BIVI 21.28
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.